Emmune Revenue and Competitors
Estimated Revenue & Valuation
- Emmune's estimated annual revenue is currently $775k per year.
- Emmune's estimated revenue per employee is $155,000
Employee Data
- Emmune has 5 Employees.
- Emmune grew their employee count by -29% last year.
Emmune's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder | Reveal Email/Phone |
2 | Accounting and Operating Director | Reveal Email/Phone |
3 | Director In Vivo Pharmacology | Reveal Email/Phone |
4 | Research Scientist | Reveal Email/Phone |
5 | Assistant Scientist | Reveal Email/Phone |
Emmune Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is Emmune?
Emmune, Inc. is a start-up biotechnology company that has a novel approach for treating and preventing HIV infection. We engineered a synthetic antibody from the receptors that HIV uses to infect T cells, CD4 and CCR5. Because this synthetic antibody, known as “eCD4-Ig,†is built from the viral receptor and co-receptor, it recognizes 100% of HIV-1 isolates. A single intramuscular inoculation with an AAV vector expressing eCD4-Ig protected monkeys from multiple intravenous challenges with live virus.
keywords:N/AN/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 5 | 25% | N/A |
#2 | $0.4M | 5 | -17% | N/A |
#3 | $0.8M | 5 | -29% | N/A |
#4 | $0.4M | 6 | 100% | N/A |
#5 | $0.9M | 6 | -45% | N/A |